Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Rating Lowered by Zacks Research

by · The Markets Daily

Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) was downgraded by Zacks Research from a “hold” rating to a “strong sell” rating in a report released on Monday,Zacks.com reports.

Several other research analysts also recently issued reports on the company. Guggenheim upped their price objective on Monte Rosa Therapeutics from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, June 30th. Weiss Ratings upgraded shares of Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday, May 11th. Wells Fargo & Company decreased their price target on shares of Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a research report on Wednesday, March 18th. Wall Street Zen downgraded shares of Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Finally, JPMorgan Chase & Co. lifted their price target on shares of Monte Rosa Therapeutics from $30.00 to $31.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. Seven equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $33.33.

Check Out Our Latest Research Report on GLUE

Monte Rosa Therapeutics Stock Up 4.9%

Shares of GLUE stock opened at $24.40 on Monday. The firm has a market capitalization of $2.06 billion, a P/E ratio of -16.49 and a beta of 1.56. Monte Rosa Therapeutics has a twelve month low of $4.12 and a twelve month high of $25.77. The stock’s fifty day simple moving average is $19.52 and its 200 day simple moving average is $18.98.

Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.06). The firm had revenue of $4.21 million during the quarter, compared to the consensus estimate of $10.95 million. Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative return on equity of 40.99%. As a group, equities research analysts expect that Monte Rosa Therapeutics will post -1.23 EPS for the current fiscal year.

Insider Activity

In related news, COO Jennifer Champoux sold 2,175 shares of Monte Rosa Therapeutics stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $20.00, for a total transaction of $43,500.00. Following the completion of the transaction, the chief operating officer owned 62,371 shares of the company’s stock, valued at $1,247,420. This trade represents a 3.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Anthony M. Manning sold 10,000 shares of the business’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $23.11, for a total transaction of $231,100.00. Following the completion of the transaction, the director owned 10,000 shares in the company, valued at approximately $231,100. The trade was a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 87,623 shares of company stock valued at $1,871,979. Company insiders own 6.40% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Seven Fleet Capital Management LP grew its stake in Monte Rosa Therapeutics by 463.3% during the first quarter. Seven Fleet Capital Management LP now owns 22,530 shares of the company’s stock worth $371,000 after purchasing an additional 18,530 shares during the period. Bank of America Corp DE lifted its stake in Monte Rosa Therapeutics by 73.3% in the first quarter. Bank of America Corp DE now owns 387,542 shares of the company’s stock valued at $6,375,000 after buying an additional 163,971 shares during the period. Janus Henderson Group PLC bought a new position in shares of Monte Rosa Therapeutics during the 1st quarter worth approximately $11,294,000. Empowered Funds LLC grew its position in shares of Monte Rosa Therapeutics by 9.8% during the 1st quarter. Empowered Funds LLC now owns 305,398 shares of the company’s stock worth $5,024,000 after buying an additional 27,321 shares during the period. Finally, Exome Asset Management LLC acquired a new stake in shares of Monte Rosa Therapeutics during the 1st quarter worth approximately $2,953,000. 79.96% of the stock is owned by institutional investors and hedge funds.

About Monte Rosa Therapeutics

(Get Free Report)

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.

Further Reading